Table 8

Medium dose of GC, the medium number of oral ulcers (OU), the Physician Global Assessment and the Patient Global Assessment at baseline and at the end of the follow-up period

ADAIFXTotalTest for meanTest for median
Mean±SDMedian (25–75 percentile)Mean±SDMedian (25–75 percentile)Mean±SDMedian (25–75 percentile)P valueP value
Medium dose of GC at baseline15.83±11.4110 (7.5 to 25)13.41±11.6910 (7.5 to 10)14.5±11.4810 (7.5 to 20)0.5140.333
Medium dose GC at the end of follow-up3.89±3.123.75 (2.5 to 5)3.86±5.512.5 (0 to 5)3.88±4.542.5 (0 to 5)0.9860.449
Diff. medium dose of GC follow-up vs baseline−11.94±12.38−7.5 (−22.5 to −2.5)−9.55±12.95−6.88 (−10 to −2.5)−10.63±12.6−7.5 (−16.25 to −2.5)0.5560.652
Medium number of OU at baseline1.83±0.922 (1 to 2)1.73±0.72 (1 to 2)1.78±0.82 (1 to 2)0.6820.872
Medium number of OU at the end of follow-up0.44±0.510 (0 to 1)0.55±0.670 (0 to 1)0.5±0.60 (0 to 1)0.6020.757
Diff. medium number OU follow-up vs baseline−1.39±0.7−1 (−2 to −1)−1.18±0.66−1 (−1 to −1)−1.28±0.68−1 (−1.5 to −1)0.3440.39
Physician Global Assessment at baseline72.5±12.9872.5 (65 to 80)73.18±17.0880 (65 to 80)72.88±15.1977.5 (65 to 80)0.890.647
Physician Global Assessment at the end of follow-up14.72±19.745 (0 to 20)19.05±17.6510 (10 to 25)17.05±18.5210 (0 to 25)0.4750.213
Diff. Physician Global Assessment follow-up vs baseline−57.78±24.27−60 (−75 to −40)−52.86±30.89−60 (−70 to −40)−55.13±27.78−60 (−75 to −40)0.5880.702
Patient Global Assessment at baseline79.44±16.5390 (70 to 90)80±14.4780 (70 to 90)79.75±15.2380 (70 to 90)0.910.901
Patient Global Assessment at the end of follow-up16.67±207.5 (0 to 30)19.32±16.6420 (5 to 30)18.13±18.0315 (0 to 30)0.650.355
Diff. Patient Global Assessment follow-up vs baseline−62.78±27.98−65 (−85 to −55)−60.68±26.65−65 (−75 to −50)−61.63±26.92−65 (−82.5 to −50)0.81712
  • ADA, adalimumab; GC, glucocorticoids; IFX, infliximab.